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Abstract
Background: Urokinase plasminogen activator (uPA), its receptor uPAR and serine
protease inhibitors PAI-1 or PAI-2 play key roles in tissue membrane remodeling and
invasion of basement membranes by induction of a fibrinolytic pathway. Earlier studies
reported that uPA and PAI-1 protein levels in breast carcinomas assist in prediction of
response to chemotherapy. Our goal is to develop molecular signatures of candidate
genes and identify novel relationships with these four protein biomarkers that
demonstrate clinical utility for assessment of breast carcinoma outcomes.
Methods: This retrospective study used de-identified biomarker results and clinical
outcomes from primary breast cancers that were stored in an IRB-approved Database.
ELISA analyses of uPA, uPAR and PAI-1 performed using IMUBIND kits (American
Diagnostica Inc.) used cutoff values previously reported. Estrogen (ER) and progestin
receptor (PR) assays were performed either by EIA (Abbott Labs) or by radioligand
binding (NEN/DuPont). Relative expression levels of 22,000 genes were determined by
microarray using RNA extracted and amplified from Laser-Capture Microdissection (LCM)
procured breast carcinoma cells. Violin plots, scatter grams, univariable Cox regression
and survival analyses were performed by R Studio version 3.4.1.
Results: Patient age was not significantly associated with level of either uPA, uPAR or
PAI-1 protein, while Violin plots showed protein content of biomarkers was related to
either ER or PR status of the primary. Examination of expression revealed that either ERor PR- breast cancers expressed elevated levels of uPA, uPAR and PAI2 genes
compared to that of ER+ or PR+ carcinoma cells. Scatter plots revealed inverse
relationships between ER/PR protein levels and expression of uPA, uPAR and PAI-2,
whereas HER2 status was unrelated to either protein content or gene expression for each
relationship examined. Interrelationships analysis revealed an elevation of uPAR content
in pre-menopausal cancer and increased PAI-1 expression in node negative cancers.
When carcinomas were sorted by urokinase biomarker levels, qPCR expression of RERG
and NQO-1 genes were elevated in uPA- lesions while CD34 and EDG-1 genes were
elevated in uPAR- cancers. However, ERBB4 gene expression was elevated in PAI-1+
carcinomas. Furthermore, Cox regression analyses revealed relationships of ER/PR
status and uPA system members with regard to clinical outcomes of breast cancer.
Conclusions: Expression of either uPA, uPAR, PAI1 or PAI2 genes was significantly
elevated in either ER- or PR- carcinomas similar to observed elevation of protein content
in ER-/PR- carcinomas, strongly suggesting relationships between sex-hormone activity
and regulation of urokinase plasminogen activator system in breast cancer. This was
supported by results showing protein content of uPA system members was related to
ER/PR status of the primary lesion. Use of LCM-procured breast carcinoma cells
uncovered relationships between expression of several known cancer-associated genes
and protein content of uPA system members. Collectively, results indicate evaluation of
ER and PR protein of the primary breast cancer biopsy combined with analyses of uPA,
uPAR and PAI-1 protein content improve assessment of clinical outcomes.
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1 | Introduction
Current Status and Molecular Approaches for Management of Breast Carcinoma
Significant advancements in screening and detection methods as well as the use
of genomic profile testing and design of novel therapeutics in recent decades (e.g., [1, 2])
have improved personalized treatment options for patients with breast carcinomas.
However, vast challenges remain regarding early screening, treatment of receptor
negative subtypes and understanding the mechanisms of cancer metastasis [3, 4]. The
development of antibody conjugated nanoparticles [5, 6], treatment regimens [7] and
utilization of biomarkers [8] hold great promise for improving the management of breast
cancer in the decades to come.
Conventional Biomarkers Used in the Management of Breast Cancer
The standard of care for the management of breast cancer includes the
assessments of levels of ER, PR and HER2 protein in the tissue biopsy (e.g., [9-11]). For
instance, patients with breast cancers exhibiting a biomarker subtype of ER+/PR+/HER2typically have a better prognosis and those patients with a biomarker subtype of
ER+/PR+/HER2+ are candidates for hormonal treatments (e.g. Tamoxifen, Letrazole) as
well as treatment with Herceptin or other humanized antibody based therapies whereas
patients with triple negative breast cancers have poor survival and few treatment options
other than chemotherapy, radiation and surgical excision of cancers (e.g., [10, 12-15]).
Clinically relevant cut-off values for assays, which quantified the biomarkers, were
established previously for each receptor that indicated potential for response to drug
therapy regimens (e.g., Tamoxifen, Herceptin).
principal
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immunohistochemical-based procedures. Due to the lack of assay standardization and
related problems, the College of American Pathologists (CAP) and the Society for Clinical
Oncology (ASCO) established Guidelines for improving uniformity of measurements and
reporting of IHC results [10, 15, 16].
Although conventional biomarkers (e.g., ER, PR and HER2 proteins) have
demonstrated utility in management protocols of breast cancer, improvements in personal
treatment plans are at the forefront of cancer research. Genomic screens (e.g., gene
expression profiles) have been developed which assess expression levels for genes
whose actions and protein products are associated with breast cancer behavior. For
instance, an FDA-approved microarray test known as MammaPrintTM uses expression of
70 genes to assess risk of breast cancer development and risk of recurrence ([17-19],
website: https://www.agendia.com/our-tests/mammaprint/).
Review of Plasminogen Activator System and its Role in Cancer Behavior
A ubiquitous system known as the urokinase plasminogen activator (uPA) system
is a proteolytic enzyme system consisting of 4 gene members, which collectively remodel
tissue basement membranes (e.g., [20, 21]). The system consists of urokinase
plasminogen activator (uPA), which is a serine protease, its respective uPA receptor
(uPAR) which is associated with the extracellular components of a target cell, and two
inhibitors of uPA association with uPAR (PAI-1 and PAI-2). One of the principal functions
of the uPA system is to convert plasminogen to plasmin to aid in the dissolution and
breakdown of fibrin at clot sites in blood vessels. In addition to the dissolution of clots, the
uPA system also has reported roles in a range of biochemical processes such as control
of inflammation, angiogenesis, embryogenesis, wound healing and cellular apoptosis
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[22]. From a clinical standpoint, the uPA system is widely documented in processes of
tumor migration, angiogenesis ([23, 24]), modulation of tumor microenvironments and
metastasis in a number of cancers such as lung [25], breast (Harbeck et al. 2017), ovarian
[26, 27], endometrial [27] and pancreatic [28]. However, it is critical to consider that
reports of the efficacy of uPA system members as prognostic markers in other cancers
(i.e., other than in breast carcinomas) remain contradictory [29].
The role of the uPA system in ECM degradation and cellular migration was first
summarized by literature reviews in the context of proposed mechanisms leading to
cancer metastasis [23, 30, 31]. Following early reports, extensive studies in vitro that
utilized migration assays revealed that the uPA system directly regulates the rate of
cellular migration. For instance, it was observed that expression of uPA, uPAR and PAI1 was up-regulated in human cancer lines wherein uPA and uPAR protein was
concentrated at cellular perimeters [32-34]. Preliminary findings warranted further
investigations of the presence of uPA system members in ECM invasion. Numerous
findings revealed that the enzymatic activity of uPA was significantly decreased when
cells were treated with antibodies and delayed ECM invasion was observed. Collectively,
the role of uPA system members in cancer migration was substantiated by
comprehensive studies in vivo.
The translation for findings of studies with cells in culture and from experimental
animal models to human cancer remains a challenge for researchers and clinicians. Thus,
early studies were conducted to analyze expression or content of uPA, uPAR, PAI-1 and
PAI-2 proteins in relation to the prognosis and survival of human breast cancer patients.
Reviews by Duffy [35, 36] reported that uPA protein content was significantly elevated in
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malignant breast lesions relative to that of benign or normal breast tissues. Subsequent
investigations of uPA demonstrated it could be used as a single prognostic marker for
human breast cancer [37]. The utility of the uPA system as biomarkers was expanded by
studies that found uPA protein content of a breast cancer served as a strong predictor of
prognosis equal to that of nodal status and more predictive than either estrogen receptor
or Cathepsin D levels [38-40]. Additional studies revealed correlations of PAI-1 protein
content with cancer aggressive behavior and clinical outcomes (e.g., [38]) as well as the
utility of uPA/PAI-1 protein levels when used in conjunction with PAI-1 as a prognostic
marker.
Clinical Application of the uPA System
The uPA system has been studied regarding cancer outcomes for nearly three
decades, with one of the first suggestions for use as a prognostic marker by Duffy (cf.
[20]). Following the original report of Duffy [41], multiple studies [29, 38, 40] demonstrated
use of uPA/PAI-1 expression levels as predictors of cancer outcomes in node-negative
breast cancer. At the turn of the millennium, large investigations confirmed the use of
quantified uPA and PAI-1 from breast cancer patients as a measure for assessment of
treatment response, progression and outcome [42-44]. Furthermore, breast cancers
exhibiting high uPA/PAI-1 levels are associated with patients with poor prognosis, yet are
most responsive to adjuvant chemotherapy [40, 45]. Additionally, patients having high
uPA/PAI-1 levels in node negative breast cancers that are ER+ positive may benefit from
anti-HER2 therapy in HER2+ breast cancer patients. Currently, the American Society of
Clinical Oncology (ASCO) encourages medical oncologists to utilize quantified uPA/PAI1 levels in patients to direct decisions regarding adjuvant chemotherapy in early-stage
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and node-negative breast cancers [46]. A major question remaining was related to the
relationships of either uPA, PAI-1 or uPAR protein content in the context of the estrogen
receptor (ER) or progestin receptor (PR) status of the primary breast carcinoma.
Goals and Focus of Thesis Research
The goals of translational research in the Hormone Receptor Laboratory include
the development and application of scientific discoveries in the laboratory to precision
medicine for improving clinical management of cancer patients. The original
investigations reported, using extensive data mining approaches of existing databases in
my mentor’s laboratory, are focused on relationships of the protein content of the
biomarkers, uPA, uPAR and PAI-1 in primary breast cancer biopsies with other clinical
features of the carcinomas (e.g., nodal status) and of the patients (e.g., menopausal
status) to determine if there are alternative biomarker combinations (e.g., with either ER
or PR status) that better predict clinical outcomes breast cancer. In addition, I extracted
previously reported gene expression results obtained via microarray of RNA extracted
from LCM-procured breast carcinoma cells (e.g., [46-52]) to compare with clinical
outcomes and carcinoma-based parameters for the study populations of breast cancer
patients. I am reporting expanded analyses of retrospective studies of de-identified
biomarker results and de-identified clinical outcomes that were collected previously and
stored in comprehensive databases established previously by my mentor. Investigations
described here showing the combined clinical value of ER and PR determinations of the
primary breast cancer biopsy with those for uPA, uPAR and PAI-1 protein content are an
extension of an earlier report from our laboratory [53].
Unique Parameters of These Investigations
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Each assay of either uPA, uPAR or PAI-1 protein content was performed
previously in the presence of a reference specimen developed specifically for Quality
Assurance of analyses of these biomarkers (e.g., [26, 27, 53, 54]). Furthermore, protein
content of either ER, PR or HER2, conventional biomarkers used in breast carcinoma
clinical management (e.g., [9, 11]) were quantified previously using FDA or state of the
art methods in the presence of reference specimens (e.g., refs 11, 57, 59, 60). Gene
expression measurements, collected earlier, were performed with RNA extracted from
LCM procured breast carcinoma cells in a non-destructive manner (e.g., [55]), without the
interference of normal cellular components (e.g., stromal cells). The final analyses have
been to correlate levels and distribution of uPA, uPAR and PAI-1 protein expression in
primary breast cancer biopsies with expression of genes of interest in relationship to
clinical outcomes. Dr. Wittliff and I will prepare the data in such a way that results will be
available for use in the design of new clinical trials evaluating the prognostic significance
of combinations of the analytes, uPA, uPAR and PAI-1, with ER, PR and HER2 protein
levels.

2 | Materials & Methods
REMARK
Summaries of patient and specimen characteristics are displayed by REMARK
tables [56] for the two distinct populations analyzed in this study. The first patient
population summary provided in Table 1 represents those patients whose tissue biopsy
measurements of uPA, uPAR and PAI-1 were used in the investigations outlined in the
Results Section. Protein biomarker measurements were performed by earlier
investigators in the laboratory according to the protocols described for determination of
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urokinase plasminogen activator system members [26, 27, 54]. A summary of patient
characteristics and tissue-based measurements for the population used in the microarray
studies is given in Table 2. Patients were treated with standard of care of time of tissue
biopsy collection and tissue measurements were performed according the protocols
presented earlier (e.g., [11, 54, 57]).

15
Table 1. Clinico-pathological properties of study population of primary breast
carcinomas and patients used in analysis of biomarker protein status.
Continuous Variables
Age (yrs)
Tumor Size (mm)
Progression Free Survival (mos)
Overall Survival (mos)
Discrete Variables
Menopausal Status (n=749)
Premenopausal
Postmenopausal
Unknown
Biomarker Measurements (protein)
uPA
uPAR
PAI-1
PFS Events
PFS Censored
OS Events
OS Censored
Pathology of Primary
IDC
ILC
IDC + ILC
Other Histologic Types
Nodal Status (n=105)
N0
N 1–3
N >3
unknown
Tumor Grade (n=105)
1
2
3
4
unknown
Tumor Stage (n=105)
0
1
2
3
4
unknown
Steroid Receptor Status (n=498)a
ER+
ER–
PR+
PR–
HER2 status (n=425)
HER2+
HER2–

Mean (sd)
55.0 (14.5)
29.8 (14.6)
Median (IQR)
52 (2–77)
62.5 (33–78)
n (%)
359 (47.9)
386 (51.5)
4 (0.6)
745
616
749
11 (10.0)
99 (90.0)
27 (24.5)
83 (75.5)
80 (76.2)
7 (6.7)
1 (1.0)
17 (16.2)
48 (45.7)
27 (25.7)
17 (16.2)
13 (12.4)
10 (9.5)
32 (30.5)
38 (36.2)
2 (1.9)
23 (21.9)
4 (3.8)
26 (24.8)
50 (47.6)
9 (8.6)
9 (8.6)
7 (6.7)
263 (52.8)
235 (47.2)
271 (54.4)
227 (45.6)
254 (59.8)
171(40.2)

aCutoff values for ER and PR are described in the methods. bCutoff values for HER2 protein levels for the

NEN/DuPont ELISA was 1.7 hnu/g protein, while that used for the TRITON Diagnostics EIA was 129.9 hnu/mg
protein.
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Table 2. Clinico-pathological properties of microarray study population of primary breast
carcinomas and patients.
Continuous Variables
Age (yrs)
Tumor Size (mm)
Progression Free Survival (mos)
Overall Survival (mos)
Discrete Variables
Menopausal Status
Premenopausal
Postmenopausal
Unknown
Race
White
Black
Other
PFS Events
PFS Censored
OS Events
OS Censored
Pathology of Primary
IDC
ILC
IDC + ILC
Other Histologic Types
Nodal Status
N0
N 1–3
N >3
unknown
Tumor Grade
1
2
3
4
unknown
Tumor Stage
0
1
2
3
4
unknown
Steroid Receptor Statusa
ER+
ER–
PR+
PR–
HER2 status (n=45)b
HER2+
HER2–

Mean (sd)
58.4 (14.9)
29.8 (16.3)
Median (IQR)
57 (26.0–82.5)
65 (41.0–89.5)
n (%)
58 (23.5)
135 (54.6)
54 (21.9)
211 (85.4)
34 (13.8)
2 (0.8)
96 (38.9)
151 (61.1)
75 (30.4)
172 (69.6)
201 (81.4)
15 (6.1)
2 (0.8)
29 (11.7)
126 (51.0)
55 (22.3)
46 (18.6)
20 (8.1)
14 (5.7)
69 (27.9)
94 (38.1)
1 (0.4)
69 (27.9)
3 (1.2)
60 (24.3)
140 (56.7)
35 (14.2)
4 (1.6)
5 (2.0)
146 (59.1)
101 (40.9)
151 (61.1)
96 (38.9)
28 (62.2)
17 (37.8)

aCutoff values for ER and PR are described in the methods. bCutoff values for HER2 protein levels for the

NEN/DuPont ELISA was 1.7 hnu/g protein (7+ of 14 biopsies), while that used for the TRITON Diagnostics EIA was
129.9 hnu/mg protein (21+ of 31 biopsies).

17
Determination of plasminogen activator system biomarkers
ELISA analyses previously quantified uPA, uPAR and PAI-1 levels using
IMUBIND kits (formerly American Diagnostica Inc., Greenwich, CT; currently BioPacific
Diagnostics, Inc., Bellevue, WA) applying cutoff values previously reported [38]. Cutoff
values of 3.0, 2.9 and 2.2 ng/mg protein were utilized for protein measurements of
biomarkers uPA, uPAR and PAI-1, respectively. Biomarker cutoff values for uPA and PAI1 were determined in accordance with clinically defined parameters [38], whereas the
cutoff value that I employed for uPAR protein was the median of 614 measurements from
the patient population. Kits for assessing PAI-2 protein were unavailable at the time of
these analyses.
Biochemical analyses of uPA, uPAR and PAI-1 were performed as described
previously [26, 27, 53, 54] using a sandwich ELISA procedure (IMUBIND, American
Diagnostica Inc., Greenwich, CT; currently BioPacific Diagnostics, Inc., Bellevue, WA).
The uPA assay recognizes pro-uPA, high molecular-weight uPA, receptor-bound uPA
and uPA complexed with PAI-1 and PAI-2. With the uPAR assay, both soluble and native
(membrane-associated) uPAR as well as complexes of either uPAR/uPA or
uPAR/uPA/PAI-1 are all recognized. The PAI-1 assay determined both active and inactive
forms of free PAI-1 and PAI-1 complexes according to the manufacturer [53, 54]. The
final concentration of each analyte was expressed in ng of uPA, uPAR or PAI-1 per mg
extract protein.
Determination of estrogen receptor and progestin receptor protein levels
Estrogen receptor and progestin receptor protein levels were determined
previously using either the Abbott Laboratories (North Chicago, IL) enzyme immunoassay
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(EIA kit) or the radio-labeled ligand binding assay (NEN/DuPont kit, Wilmington, DE) on
freshly prepared cytosols as described previously [9, 11, 57, 58]. Using the latter FDAapproved kits which employ either [3H]estradiol-17β or [3H]R5020 depending upon the
receptor type being determined, specific ligand binding capacity, reflecting both receptor
level, expressed as fmol/mg cytosol protein, and activity expressed as the apparent
dissociation constant (Kd value as M) were determined previously by Scatchard analysis.
Determination of ER and PR levels by EIA employed an FDA-approved kit formerly
distributed by Abbott Laboratories [11, 57]. The distribution according to ER and PR
status of the primary breast carcinomas used in my investigations is given in Tables 1
and 2.
Detection of HER2/neu in primary breast cancers Seth
HER2/neu oncoprotein status was measured in primary breast carcinomas using
either one of the two experimental antibody-based assays as described previously [11,
54, 59, 60]. Cutoff values measured in HER2-neu units (hnu) utilized for NEN/DuPont
ELISA (which became Oncogene Science Diagnostics) was 1.7 hnu/µg protein (7+ of 14
biopsies), while that used for the TRITON Diagnostics EIA was 129.9 hnu/mg protein (21+
of 31 biopsies).
Assessment of gene expression in LCM-procured cells using microarray analyses
Results described in my investigations were collected previously from de-identified
primary breast cancer carcinomas obtained from 1988 – 1996, in IRB-approved studies
and stored in de-identified databases of the Hormone Receptor laboratory which holds
CLIA and Commonwealth of Kentucky licenses [48, 49, 51, 52, 55]. Selection and
examination of the patient population were performed using REMARK criteria [1] as
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described previously [47-50, 52, 61]. Patients were treated with standard of care at time
of diagnosis. Patient-related characteristics and tissue-based properties (Table 1), stored
as de-identified parameters in our unique comprehensive databases were explored to
determine relationships between relative gene expression and clinical parameters.
Briefly, tissue sections of frozen de-identified tissue biopsies were processed
previously for Laser Capture Microdissection (LCM) with a PixCell IIe™ Instrument
(Arcturus/Thermo Fisher), as described previously [48, 49, 51, 52, 55, 58]. As reported
earlier [55, 62, 63], total RNA was extracted from LCM-procured cells and amplified
before microarray as described earlier. Relative expression levels of each of 22,000
genes obtained from microarray uniquely represented only those mRNA species of breast
carcinoma cells [49, 51, 55, 58, 62, 63].
Assessment of gene expression in breast carcinoma tissue sections using qPCR
analyses
Using qPCR results determined in our laboratory by other investigators [48, 49, 51,
52, 64], gene expression levels for 110 genes, known to be associated with various
cancers, were used in my studies to explore relationships with members of the urokinase
plasminogen activator system.
Univariable Cox regression and Kaplan-Meier Analyses
Statistical computations, violin plots and Kaplan-Meier plots were performed using
R version 3.2.5. Utilizing commands from R package survival [65] univariable Cox
regressions of expression levels of each gene candidate estimated p-values of hazard
ratios (HR) to determine genes suggesting clinical significance. P-values were adjusted
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for multiple comparisons using the Benjamini and Hochberg (BH) method with <0.30
selected as the “discovery” cutoff as applied earlier [47, 66-68].
Univariable Cox regression was performed on each gene candidate using relative
expression levels to discern relationships with Progression Free Survival (PFS) and
Overall Survival (OS). This allows the use of relative gene expression values as a single
covariate to investigate extent to which expression levels of a single gene in the cohort
predicted PFS or OS of breast cancer patients. Hazard ratios were derived from
univariable Cox regression models and calculated for each of the candidate genes.
Relative gene expression levels determined with LCM-procured carcinoma cells
from 247 patients were stratified above and below the median for each univariable
significant gene candidate. Adjusted p-values (BH method) were derived from Log-Rank
Tests comparing survival times between groups. Since ER and PR status of a breast
cancer is related to a patient’s prognosis [10, 11, 47, 48, 58], analyses of candidate gene
expression in LCM procured cells according to steroid hormone receptor status of the
primary carcinoma biopsy were performed. Survival curves for various groups were
visualized in Kaplan-Meier plots with the number of patients at risk at various time points
displayed in a table below each plot.

3 | Results
3.1 | Interrelationships of biomarker protein status of the primary breast carcinoma
as a function of patient age

Scatter plots were constructed in order to ascertain the relationship between
patient age and quantified biomarker protein in the primary breast cancer (Figure 1).
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Linear regression analyses were performed and a p-value of < 0.05 was considered
significant. Our results indicated that age of the patient was not significantly associated
with the level of either uPA, uPAR or PAI-1 biomarker protein in the primary breast cancer.

Figure 1. Scatter plots analyses of patient age versus protein biomarker content of
members of the urokinase plasminogen activator system. a) Relationship of age versus
[uPA], n=217 ; b) Age versus [uPAR], n=218 ; c) Age versus [PAI-1], n=218
a

b

c

3.2 | Determinations of biomarker protein status as a function of either ER or PR
protein status of the primary breast carcinoma
Violin plots were computed of biomarker protein content (ng biomarker/mg total
protein) of each uPA system member according to either ER or PR status of the primary
carcinoma. Using highly quantified assays for steroid receptor status that have received
FDA approval ([58], DuPont 1988 PR Assay Kit, Abbott 1988 ER-EIA monoclonal assay,
DuPont 1989 ER Assay Kit, Abott 1998 PGR-EIA monoclonal assay), cutoff values were
utilized as reported earlier (e.g., [11, 57, 58]). An adjusted p-value of < 0.30 was employed
as the discovery cut-off for significance as described previously [47].
Results of analyses are displayed in which either ER or PR protein was measured
either by radio-ligand binding or by EIA (Figure 2). When either ER or PR levels were
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measured by radio-ligand binding, it was observed that protein content of both uPA and
uPAR were elevated in receptor positive carcinomas compared to those of receptor
negative carcinomas (Figure 2 a-b and d-e). In contrast, it was observed that protein
content of uPAR was significantly elevated in ER- cancer biopsies compared to those
ER+ specimens as measured by EIA (Figure 2h). Furthermore, protein levels of PAI-1
were significantly elevated in either ER or PR negative cancers measured by EIA
compared to receptor positive cancers (Figure 2 i,l).
For each relationship, Violin plots juxtaposed distributions of uPA, uPAR or PAI-1
expression values of either ER+ vs ER- or PR+ vs PR- primary breast cancers to examine
potential regulation by these sex steroid hormones. Distributions were compared using
an unpaired independent two-sample Mann-Whitney-Wilcoxon test. Plots display the
kernel of the distribution of log uPA, uPAR or PAI-1 expression for either ER or PR
subtypes from breast carcinomas. Median of log relative expression is indicated by a
white circle and the interquartile range is denoted with a black bar.

Figure 2. Relationship of biomarker protein status of the uPA system with ER or PR status
of the primary carcinoma. Steroid receptor protein content (ER or PR) in plots a-f was
determined by radio-ligand binding, and content in plots g-l was assessed by EIA.
Adjusted p-values of each comparison are shown above each pair.
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3.3 | Assessment of biomarker protein status as a function of HER2 protein status
of the primary breast carcinoma

To assess the relationship between HER2 protein status of a primary breast
carcinoma and uPA system biomarker, violin plots were constructed (Figure 3). An
adjusted p-value of < 0.30 was employed as the cutoff value for significance. Our
analyses indicated that HER2 status of the primary breast cancer was not related to
protein content of either uPA, uPAR or PAI-1.

Figure 3. Violin plots of protein biomarker content of urokinase plasminogen activator
system members comparing distributions by HER2 status. Breast carcinomas were
classified as either HER2+ or HER2- according to cutoff values for measurements
obtained from either NEN/DuPont or TRITON assays as described in the Methods &
Materials.
a

b

c

3.4 | Analysis of biomarker gene expression of the uPA pathway members as a
function of ER or PR protein status of the primary breast carcinoma
Since ER is used routinely as a biomarker for prediction of breast cancer
recurrence and therapy selection such as Tamoxifen administration (e.g., [10]), relative
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expression of either uPA, uPAR, PAI-1 or PAI-2 genes was examined through
construction of Violin plots according to ER+ or ER- status of the primary lesion (Figure
4). An adjusted p-value of < 0.30 was employed as a discovery cut-off for significance
(e.g., [47]). Note that relative gene expression was estimated using LCM-procured breast
carcinoma cells as described in Methods & Materials. These analyses revealed that
expression of the uPA gene was significantly elevated in ER- cells compared to ER+ cells
(Figure 4a). Analyses also indicated that expression of either uPAR or PAI-2 genes was
significantly elevated in ER- breast cancer cells compared to ER+ cells at an adjusted pvalue of < 0.001 (Figure 4b and d). Expression of PAI-1 gene was not significantly
expressed in regard to ER status of the primary lesion.
In addition, PR status of the primary lesion was evaluated in relation to expression
of each candidate gene in LCM-procured cells. Therefore, Violin plots of PR+ and PRlesions were constructed in relation to relative gene expression of each gene of interest
(Figure 4). Analyses indicated that expression of uPA and its respective receptor, uPAR,
were significantly elevated in PR- lesions (Figure 4 e-f). In comparison to PR+ cells,
elevated expression of both PAI-1 and PAI-2 genes was detected in PR- breast cancer
cells (Figure 4 g-h).

Figure 4. Violin plots utilizing relative expression of genes of the uPA system estimated
by microarray compared to either ER or PR status of the breast primary lesion for 247
patients. Breast carcinomas were classified as either ER+ or ER- and either PR+ or PRutilizing measurements obtained by either EIA or radio-ligand binding.
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To determine if there is a relationship between either ER or PR protein levels in a
primary lesion and relative expression of each gene of interest, scatter plots were
constructed. Total ER or PR protein content (fmol /mg P) of each primary breast
carcinoma was plotted as a function of relative expression for each gene of interest
(Figure 5). Note that since microarray analyses also provided results of PAI-2 gene
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expression in LCM-procured cells, determination of these relationships was possible with
each of the four members of the plasminogen activator system.
Representative analyses of statistically significant analyses are shown in Figure 5.
These data indicated a negative relationship between ER protein content and relative
expression of uPA, uPAR and PAI-2 genes that was statistically significant (Figure 5 ac). When the relationship between PR protein content of the cancer biopsies was
examined in relation to expression of each candidate biomarker, expression of uPAR and
PAI-2 genes were significant (Figure 5d-e).

Figure 5. Relationship of ER protein versus candidate gene expression a-c) and PR
protein content in relation to relative expression of candidate genes d-e). Of the 8 possible
relationships of gene expression to steroid receptor status, only 5 exhibited statistical
significance. Representative relationships of ER protein versus candidate gene
expression (a-c) and PR protein content in relation to relative expression of candidate
genes (d-e) are shown.
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3.5 | Interrelationships of relative gene expression of uPA, uPAR, PAI-1 and PAI-2
as a function of HER2 protein status of the primary breast carcinoma

The HER2/neu protein status of a primary breast cancer is considered with ER and
PR as a biomarker for prediction of breast cancer outcome and selection of treatment
regimen [10, 15, 69]. Relative expression of each gene of members of the urokinase
plasminogen activator system determined by microarray was evaluated in relationship to
HER2 protein status (Figure 6). Analyses indicated that HER2 status of the primary breast
cancer was not significantly related to expression of any of the four candidate genes
analyzed.
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Figure 6. Representative violin plots utilizing microarray expression of genes of the uPA
system comparing HER2 protein status for 45 patients. Breast carcinomas were classified
as either HER2+ (n=28) or HER2- (n=17) with measurements obtained from either
NEN/DuPont or TRITON assays as described in Materials & Methods.
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|

Biomarker gene expression of the LCM-procured carcinoma cells as a

function of menopausal status of the patient
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Since the menopausal status of breast cancer patients is a clinically useful
management parameter, Violin plots were created to examine the relative expression of
each candidate gene in LCM-procured carcinoma cells and menopausal status of patients
(Figure 7). Violin plots were constructed for each gene of interest according to
premenopausal or postmenopausal status and an adjusted p-value of < 0.30 was
employed as the discovery cutoff. Patients who were 54 years of age or younger at the
time of biopsy were classified as premenopausal. Notably, expression of uPAR gene was
significantly elevated in premenopausal patients at an adjusted p-value of < 0.30 (Figure
7b).

Figure 7. Violin plots comparing microarray expression levels of each gene of interest in
LCM-procured breast carcinomas of either premenopausal (n=102) or postmenopausal
(n=145) breast cancer patients.
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3.7 | Relative expression of each biomarker gene in the uPA pathway as a function
of nodal status of the patient
Nodal status of a patient presenting with breast carcinoma is of critical importance
to clinical management ( e.g.,[10, 38]) although not all node positive breast cancers
exhibit early recurrence. Relative expression of each gene of the uPA system was
estimated in LCM-procured carcinoma cells by microarray and plotted in relationship to
either positive (n=122) or negative (n=125) nodal status for 247 patients. For this initial
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set of Violin plot analyses, patients with 1 or more nodes exhibiting breast carcinoma were
considered node positive (Figure 8).

Figure 8. Violin plots utilizing relative expression of genes of the uPA system estimated
by microarray in relationship to either positive or negative nodal status for 247 patients.
Patients with 1 or more nodes exhibiting breast carcinoma were considered node positive.
a

b

c

d
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Since nodal status of patients is also considered in different categories based upon
different patterns of breast carcinoma progression, recurrence and other clinical
outcomes (e.g., [9, 10, 38]) analyses were performed. Violin plots utilized relative
expression of either uPA, uPAR, PAI-1 or PAI-2 genes estimated by microarray of RNA
extracted from LCM-procured carcinoma cells plotted in relationship to nodal status,
either negative (n=125), 1-3 positive nodes (n=69) or >3 positive nodes (n=53) as shown
in Figure 9.
Analyses indicated that the nodal status of a patient with breast carcinoma was not
related to relative expression of either uPA, uPAR, PAI-1 or PAI-2 genes estimated by
microarray of RNA extracted from LCM-procured carcinoma cells (Figure 9).

Figure 9. Violin plots utilizing relative expression of genes of the uPA system estimated
by microarray in relationship to either negative (n=125), 1-3 positive (n=69) or >3 positive
(n=53) nodal status for 247 primary breast carcinoma patients.
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3.8 | Interrelationships of biomarker status of the primary breast carcinoma with
expression of candidate genes known to be associated with cancer
From our previous studies of gene expression in primary breast carcinomas [18,
19, 51, 58], 110 genes of interest have been identified whose expression we have
validated by qPCR using intact tissue sections from fresh frozen biopsies. Relationships
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between expression of candidate cancer-related genes and protein biomarker content
were analyzed through construction of Violin plots (Figure 10). Relative gene expression
estimated by qPCR, an adjusted p-value of < 0.30 employed for significance and
biomarker cutoff values described previously were employed in these analyses. It was
observed that MSX1 expression was significantly elevated in uPA+ cells (Figure 9a),
whereas expression of RERG was elevated in uPA- carcinomas (Figure 9b). In contrast,
results indicated that LRBA expression was significantly elevated in uPAR- carcinomas
(Figure 9c). Subsequent analyses revealed that SIAT8A expression was significantly
elevated in uPAR+ breast cancer (Figure 9d). When qPCR gene expression was
examined in relation to PAI-1 status it was observed that elevated expression of COMT
and TGFB1 was observed in PAI-1+ cells (Figure 9e,f).

Figure 10. Violin plots of the qPCR expression levels of representative genes known to
be associated with breast cancer as a function of plasminogen activator system protein
status (n=29 patients).
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Although the sample size was small (n=29), the expression of a number of genes
previously reported to be associated with breast carcinomas was examined as a function
of the relative expression of uPA, uPAR, PAI-1 and PAI-2 genes. Scatter plots of the
genes identified from analyses shown in Figure 10 were constructed (Figure 11). None of
the genes examined indicated their relative expression was associated with that of either
uPA, uPAR or PAI-1 genes when a p-value of <0.05 was employed for significance.

Figure 11. Scatter plots of relative expression of candidate cancer-assoicated genes
identified in Figure 10 as a function of relative gene expression of members of the
urokinase plasminogen activator system. Results shown represent microarray expression
levels for each of the genes shown.
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3.9 | Univariable Cox Regression Analyses of Relative Gene Expression According
to ER and PR Status of LCM-procured Breast Carcinoma Cells

To determine the relationship between expression of each gene from microarray
of the urokinase plasminogen activator system and steroid receptor status, Cox
regression analyses of genes were performed with regard to ER or PR status of the
primary breast cancer. An adjusted p-value of < 0.30 was selected for discovery (Tables
3 and 4). Cox regressions revealed that expression of PAI-2 in carcinoma cells was
significantly related to OS in ER+ breast cancers. In ER-breast cancers, uPAR expression
was related to prediction of PFS whereas PAI-1 expression predicted OS. Furthermore,
when carcinomas were classified according to PR status, uPA expression was
significantly related to PFS and OS of patients with PR+ primary carcinomas. In PR-
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cancers, expression of either uPAR or PAI-2 was related to prediction of PFS. Similarly,
expression of either PAI-1 or PAI-2 was related to prediction of OS in PR- breast cancer
patients from LCM-procured cells of breast carcinomas according to ER protein status.

Table 3. Univariable Cox Regression Analyses of Relative Gene Expression
According to ER Status of LCM-procured Breast Carcinoma Cells. Relative
expression of each gene was utilized for ER+ patients (n=146); relative expression of
each gene was utilized for ER- patients (n=101).
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PFS/ER+
β

HR

95% CI (HR)

p value

uPA

0.17

1.185

(0.93,1.51)

0.165

Adjusted
p-value
0.375

uPAR

0.14

1.153

(0.39,1.19)

0.421

0.561

PAI-1

0.07

1.068

(0.82,1.63)

0.660

0.660

PAI-2

-0.39

0.680

(0.8,1.43)

0.177

0.354

Gene Symbol

OS/ER+
uPA

0.21

1.231

(0.21,0.92)

0.168

0.335

uPAR

0.13

1.136

(0.92,1.66)

0.516

0.588

PAI-1

0.13

1.135

(0.77,1.67)

0.466

0.516

PAI-2

-0.83

0.437

(0.81,1.59)

0.030

0.122

PFS/ERβ

HR

95% CI (HR)

p value

uPA

-0.08

0.923

(0.14,0.76)

0.535

Adjusted
p-value
0.753

uPAR

-0.39

0.677

(0.85,1.61)

0.013

0.093

PAI-1

0.19

1.213

(0.59,1.53)

0.238

0.630

PAI-2

0.06

1.061

(0.66,1.39)

0.454

0.614

uPA

0.10

1.105

(0.05,0.44)

0.488

0.554

uPAR

-0.14

0.870

(0.86,1.86)

0.342

0.459

PAI-1

0.39

1.471

(0.51,1.45)

0.039

0.275

PAI-2

0.09

1.097

(0.74,1.66)

0.271

0.382

Gene Symbol

OS/ER-

Table 4. Univariable Cox Regression Analyses of Relative Gene Expression
According to PR Status of LCM-procured Breast Carcinoma Cells. Relative
expression of each gene was utilized for PR+ patients (n=151); relative expression of
each gene was utilized for PR- patients (n=96).
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PFS/PR+
β

HR

95% CI (HR)

p value

uPA

0.25

1.286

(0.99,1.66)

0.055

Adjusted
p-value
0.221

uPAR

0.16

1.177

(0.87,1.58)

0.282

0.342

PAI-1

0.12

1.128

(0.83,1.54)

0.443

0.443

PAI-1

-0.16

0.853

(0.6,1.22)

0.384

0.404

Gene Symbol

OS/PR+
uPA

0.39

1.481

(1.07,2.05)

0.018

0.072

uPAR

0.21

1.232

(0.89,1.71)

0.213

0.426

PAI-1

0.10

1.102

(0.77,1.58)

0.600

0.657

PAI-2

-0.15

0.864

(0.57,1.3)

0.486

0.600

PFS/PRβ

HR

95% CI (HR)

p value

uPA

-0.12

0.885

(0.55,1)

0.310

Adjusted
p-value
0.413

uPAR

-0.30

0.737

(0.97,1.35)

0.048

0.191

PAI-1

0.05

1.054

(0.7,1.12)

0.725

0.725

PAI-2

0.13

1.143

(0.79,1.41)

0.109

0.218

uPA

-0.02

0.982

(0.93,1.74)

0.894

0.894

uPAR

-0.10

0.908

(0.98,1.4)

0.522

0.696

PAI-1

0.24

1.269

(0.67,1.22)

0.137

0.274

PAI-2

0.16

1.170

(0.76,1.28)

0.084

0.212

Gene Symbol

OS/PR-

4 | Discussion
Investigations reported in this thesis are focused on relationships of the
biomarkers, uPA, uPAR and PAI-1 in primary breast cancer biopsies with other clinical
features of the carcinomas (e.g., nodal status) and of the patients (e.g., menopausal
status) to determine if there are alternative protein biomarker combinations (e.g., with
either ER or PR status) that predict clinical outcomes (progression-free survival and/or
overall survival) of breast carcinoma patients in an improved manner. In addition, I
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compared previously reported gene expression results obtained by microarray of RNA
extracted from LCM-procured breast carcinoma cells (e.g., [47-52, 58, 70]) with clinical
outcomes and carcinoma-based parameters for the study populations of breast cancer
patients. The analyses reported utilize de-identified results from retrospective studies of
biomarker determinations and de-identified clinical outcomes that were collected
previously and stored in our comprehensive databases. Investigations described here
showing the combined clinical value of ER and PR determinations of the primary breast
cancer biopsy with those for uPA, uPAR and PAI-1 protein content are an extension of
our earlier report [58].
One focus of cancer research in a modern context is to examine either the
expression of genes or to quantify biomarkers of cancer associated members in regard
to clinical and pathologic features [48, 56, 71]. Modern strategies such as the use of
commercial genomic testing, have demonstrated clinical utility (e.g., MammaPrintTM,
OncoTypeDXTM) for the management of breast cancer in addition to the use of
chemotherapy agents [12, 13, 71]. Development of treatments and tests were due in part
to investigations of cancer associated genes and proteins as it relates to patient
characteristics. Thus, interrelationships between quantified content of uPA system
proteins and clinical features such as patient age, and ER, PR or HER2 status of breast
carcinoma patients were examined.
Results revealed that an increase of uPA, uPAR or PAI-1 protein content was not
correlated with patient age. Relationships between other biomarkers for breast cancer
(e.g., ER or PR protein) in intact tissue biopsies and patient age have exhibited
associations for breast cancer patients, though the literature is conflicting (i.e., [72, 73]).
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Similarly, our findings presented in Figure 2 established relationships between biomarker
protein content of the uPA system and either ER or PR status of the primary carcinoma.
Violin plots indicated either uPA or uPAR content was elevated in carcinomas when they
also exhibited elevated levels of either ER or PR protein content as measured by radioligand binding. However, when ER or PR content was determined by EIA, receptor
negative carcinomas exhibited elevated levels of uPA content.
Differences in relations of protein content and status (i.e., Figure 2 b/h) may be
due to the type of assay employed despite utilization of standard cutoff values for both
the radio-ligand binding and the EIA assay [57]. Literature reports evidence of a weak
association of negative ER status and elevated uPA content in carcinomas were similar
to our findings when ER was assessed by EIA [74, 75]. To extend our investigation of
interrelationships between gene expression and proteins status, HER2 status was
examined in relation to biomarker protein content. No relationships were detected
between HER2 status and protein content of either uPA, uPAR or PAI-1 for our patient
population.
Interrelationship analyses utilized expression from microarray of LCM-procured
breast carcinoma cells collected under stringent conditions. In addition, IMUBIND kits
were employed to quantify uPA, uPAR and PAI-1 content using cellular extracts from
heterogeneous tissue samples of breast cancer [26, 27, 53, 54]. Thus, results presented
may reflect a heterogeneous tumor microenvironment which is composed of stromal
elements [49, 74]. Largely, results of figures 1-3 indicated that biomarker protein content
may be related to patient age and ER/PR status, but no relation with HER2 status was
observed among our patient population.
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Established relationships have been reported between uPA, uPAR, PAI-1 content
of a primary carcinoma and clinical features such as ER/PR status and outcomes [26, 27,
53, 76]. However, few studies examined relationships for both protein content and gene
expression of uPA system members within a unique patient population, such as that used
in these investigations. Our exploratory and complementary analyses, described in in
Figures 4-5, investigated gene expression results, collected from LCM-procured breast
carcinoma cells, according to either ER, PR or HER2 status of the primary. Additionally,
expression of plasminogen activator inhibitor 2 (PAI-2) gene was incorporated due to
limited research regarding its expression in breast cancer.
Our results in Figure 4 largely parallel those of analyses displayed in plots g-l of
Figure 2. Expression of either uPA, uPAR, PAI-1 or PAI-2 genes was significantly
elevated in either ER- or PR- carcinomas similar to the observed elevation of protein
content in receptor negative carcinomas (Figure 2) measured by EIA. Figure 5 delineated
the extent of relationships between expression of each uPA system member and
quantified ER or PR protein. Scatter plots revealed that expression of either uPA, uPAR
or PAI-2 appear to be negatively correlated both ER and PR protein of the primary.
Collectively, results of Figures 2, 4 and 5 largely indicate that increased protein content
or expression of uPA system members is significantly associated with receptor negative
carcinomas (i.e., ER- or PR-). Collective findings are in contrast to plots a-f of Figure 2 in
which either uPA or uPAR protein content was elevated in ER+ cells determined by a
radio-ligand binding assay.
Nodal status and menopausal status, which are clinically relevant parameters, are
documented as factors for prediction of clinical outcome, likelihood of recurrence and
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clinical management strategies for patients with breast cancer [9, 10, 38, 73, 74].
Therefore, biomarker gene expression was examined as a function of menopausal status
of patients with breast cancer. A noteworthy observation was elevation of uPAR
expression in pre-menopausal status among our patient population. Elevation of uPAR
content is associated with poor outcome [45], but few studies have examined expression
of uPAR as a function of clinically relevant parameters. An elevation of expression in postmenopausal patients compared to pre-menopausal may be a reflection of changes in ER
and PR serum levels associated with menopause in women. This finding is indicative of
a relationship menopausal status of breast cancer patients and uPAR, although our
results warrant further investigation.
Similarly, nodal status of patients with breast cancer was examined according to
gene expression of each uPA system member (Figures 8 and 9). Nodal status of each
patient was classified in two different categories due to documented differential outcomes
according to either status of nodes or number of nodes which are positive [9, 45]. A
positive nodal status was designated as the presence of one or more nodes positive in
figures 8, whereas nodal status was classified according to total number of nodes in figure
9. Collectively, PAI-1 was elevated in node positive breast carcinomas whereas the
alternate classification did not provide statistically significant differences (Figure 9). In the
context of a clinical setting, it may be useful to assign positive nodal status as one or more
nodes exhibiting breast cancer for assessment of PAI-1. However, classification of status
according to the number of nodes that are positive holds strong clinical utility for the
prediction of early recurrence and clinical outcome [38, 77].
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Interrelationships of qPCR expression of a number of genes reported to be
associated with breast cancer outcomes was studied as a function of biomarker status.
In addition, the uPA system has reported roles in processes of inflammation,
angiogenesis, embryogenesis, wound healing, cellular apoptosis tumor migration and
angiogenesis [22-24]. Expression of genes such as TGFB1 or LRBA was significantly
associated with either PAI-1 or uPAR status. Similarly, significant differences in
expression of genes MSX1, RERG, SIAT8A and COMT according to biomarker status
was observed.
The status of either uPA, uPAR or PAI-1 protein content was assigned according
to standard cut-off values provided by IMUBINDTM kits whereas expression of each gene
was estimated via qPCR on intact carcinoma tissue sections [52]. Analyses in Figure 11
employed expression obtained from microarray analysis of LCM-procured breast
carcinoma cells in which significant interrelationships were not observed. Thus, the
clinical utility of our preliminary findings warrants additional investigation in the context of
the microenvironment of breast carcinomas. Differences in expression patterns for the
genes of interest could be a reflection of the genomic profile of a heterogeneous breast
tissue sample (i.e., collection of qPCR expression) compared to that of isolated carcinoma
cells [49].
Investigations described in this thesis were focused on evaluating the combined
clinical value of ER and PR protein determinations of the primary breast carcinoma biopsy
with those for uPA, uPAR and PAI-1 protein content to improve breast cancer
management. Our studies also included examination of the expression of the genes for
each of the biomarkers under consideration.
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Expression of PAI-2 gene was significantly related to overall survival of patients
with ER+ breast cancers. In ER- carcinomas, expression of either uPAR or PAI-1 was
related to PFS or OS, respectively. In contrast, literature reports have focused on protein
content and indicate PAI-2 level is related to increased prognosis for breast cancer
patients, whereas other studies have reported no significance for the use of PAI-2 level
as a determinant of clinical outcome [78, 79]. Additionally, Gelder et al. [80] analyzed PAI2 level of cytosols prepared from ER+ primary breast cancers and discovered a significant
relationship between high PAI-2 level and length of response to Tamoxifen (i.e., first-line
therapy for recurrent breast cancer). Thus, our findings establishing the relationship
between uPAR, PAI-1 and PAI-2 genes with clinical outcomes of patients with breast
cancers exhibiting various ER status support the concept that estrogen levels are involved
in regulation of these biomarkers.
Kotzsch et al. [81] examined uPAR gene expression obtained from microarray in
breast tumor specimens for invasive ductal carcinomas. It was reported that elevated
uPAR gene expression levels in tumor cells, and not from stromal cells, was predictive of
PFS. Our findings support the work of Kotzsch et al. [81] and identify the prognostic value
of uPAR gene expression in ER- carcinomas. In breast cancer patients, it is widely known
that elevated PAI-1 level is associated with poor OS, whereas few studies have evaluated
PAI-1 gene expression. Our analyses identified a relationship between PAI-1 gene
expression and OS for ER- patients. Since ER- patients are not candidates for traditional
treatments (i.e., SERM, Raloxifene, Tamoxifen), further examination of PAI-1 gene
expression may serve as a strategy for breast cancer management as evidenced by our
findings. In PR+ patients, uPA gene expression obtained from microarray of LCM-
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procured breast carcinoma cells was significantly related to prediction of either PFS or
OS. In PR- patients, PAI-2 expression collected from LCM-procured breast carcinoma
cells was predictive of PFS and OS.
Current guidelines for the management of primary breast carcinomas instruct
clinicians to utilize analyses of ER, PR and HER2 protein levels collectively to assess risk
of recurrence and therapy selection [15, 69]. The results of the investigations reported in
this thesis strongly suggest that consideration of combinations of results from ER or PR
protein content with the measurements of either uPA, uPAR or PAI-1 protein levels of a
primary breast cancer biopsy provide improvements in assessing a patient’s clinical
outcome. Furthermore, our collective analyses of expression of genes, uPA, uPAR, PAI1 and PAI-2 as well as those for ESR1 (gene expressing ER mRNA and protein) and
PGR (gene for expressing PR mRNA and protein) using LCM-procured breast carcinoma
cells, indicated relationships between levels of biomarker mRNA and disease-free
progression and overall survival of patients.
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